Prospective Randomized Phase II Trial of Pazopanib (NSC #737754, IND 75648) Versus Placebo in Patients with Progressive Carcinoid Tumors

Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202)

E Bergsland;S Geyer;T Asmis;S Behr;P Kumthekar;M Maitland;D Niedzwiecki;A Nixon;L Schwartz;J Strosberg;A Venook;E O'Reilly;J Meyerhardt J Clin Oncol. 2025 Oct 10;43(29):3170-3183. doi: 10.1200/JCO-24-02644. Epub 2025 Sep 3.NIHMS2099573

PMid: PMID40902132 | PMC number: PMC12457709

Discordance between central vs. local response assessments in neuroendocrine tumor (NET) patients enrolled in A021202

S Geyer;M Mahoney;T Asmis;N Hall;S Karovic;M Knopp;P Kumthekar;A Nixon;E O'Reilly;L Schwartz;J Strosberg;J Meyerhardt;M Maitland;E Bergsland J Clin Oncol 39, 2021 (suppl 3; abstr 361); ASCO GI Cancers Symposium (January 15-17, 2021, virtual), poster

New strategies to improve drug development in carcinoid tumors (Alliance A021202)

E Bergsland;S Geyer;M Mahoney;T Asmis;N Hall;S Karovic;M Knopp;P Kumthekar;A Nixon;E OReilly;L Schwartz;J Strosberg;J Meyerhardt;M Maitland Neuroendocrine Tumor Research Foundation Research Symposium (November 2020), poster

Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202)

E Bergsland;M Mahoney;T Asmis;N Hall;P Kumthekar;M Maitland;D Niedzwiecki;AB Nixon;EM O'Reilly;LH Schwartz;JA Sloan;J Strosberg;J Meyerhardt J Clin Oncol 37(suppl; abstr 4005); American Society of Clinical Oncology (5/31 - 6/4/2019, Chicago IL), oral